Q4 saw a 45% net revenue increase to $10.1M, with prescription shipments up 25% and strong cash flow improvements. Gross-to-net yield rose to 22%, and cost-saving initiatives plus IP expansion position the business for continued growth and value creation.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.